MDGL vs. ALKS, IONS, FOLD, RCKT, GERN, DVAX, LGND, IRWD, YMAB, and GBIO
Should you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), Rocket Pharmaceuticals (RCKT), Geron (GERN), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), Ironwood Pharmaceuticals (IRWD), Y-mAbs Therapeutics (YMAB), and Generation Bio (GBIO). These companies are all part of the "pharmaceutical preparations" industry.
Madrigal Pharmaceuticals (NASDAQ:MDGL) and Alkermes (NASDAQ:ALKS) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations.
Alkermes received 238 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 70.84% of users gave Alkermes an outperform vote while only 68.56% of users gave Madrigal Pharmaceuticals an outperform vote.
Alkermes has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Madrigal Pharmaceuticals currently has a consensus price target of $356.73, suggesting a potential upside of 84.52%. Alkermes has a consensus price target of $35.38, suggesting a potential upside of 43.33%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Madrigal Pharmaceuticals is more favorable than Alkermes.
Alkermes has a net margin of 21.39% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Alkermes' return on equity of 16.10% beat Madrigal Pharmaceuticals' return on equity.
In the previous week, Madrigal Pharmaceuticals had 5 more articles in the media than Alkermes. MarketBeat recorded 11 mentions for Madrigal Pharmaceuticals and 6 mentions for Alkermes. Alkermes' average media sentiment score of 0.63 beat Madrigal Pharmaceuticals' score of 0.55 indicating that Alkermes is being referred to more favorably in the news media.
98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 23.9% of Madrigal Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of Alkermes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Madrigal Pharmaceuticals has a beta of -0.47, meaning that its share price is 147% less volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.
Summary
Alkermes beats Madrigal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.
Get Madrigal Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Madrigal Pharmaceuticals Competitors List
Related Companies and Tools
